Related Experiment Video
Updated: Nov 3, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
PRL-3 induces a positive signaling circuit between glycolysis and activation of STAT1/2
Esten Nymoen Vandsemb1, Morten Beck Rye1,2,3,4, Ida Johnsen Steiro1
1Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Abstract:
Multiple myeloma (MM) is an incurable hematologic malignancy resulting from the clonal expansion of plasma cells. MM cells are interacting with components of the bone marrow microenvironment such as cytokines to survive and proliferate. Phosphatase of regenerating liver (PRL)-3, a cytokine-induced oncogenic phosphatase, is highly expressed in myeloma patients and is a mediator of metabolic reprogramming of cancer cells. To find novel pathways and genes regulated by PRL-3, we characterized the global transcriptional response to PRL-3 overexpression in two MM cell lines. We used pathway enrichment analysis to identify pathways regulated by PRL-3. We further confirmed the hits from the enrichment analysis with in vitro experiments and investigated their function. We found that PRL-3 induced expression of genes belonging to the type 1 interferon (IFN-I) signaling pathway due to activation of signal transducer and activator of transcription (STAT) 1 and STAT2. This activation was independent of autocrine IFN-I secretion. The increase in STAT1 and STAT2 did not result in any of the common consequences of increased IFN-I or STAT1 signaling in cancer. Knockdown of STAT1/2 did not affect the viability of the cells, but decreased PRL-3-induced glycolysis. Interestingly, glucose metabolism contributed to the activation of STAT1 and STAT2 and expression of IFN-I-stimulated genes in PRL-3-overexpressing cells. In summary, we describe a novel signaling circuit where the key IFN-I-activated transcription factors STAT1 and STAT2 are important drivers of the increase in glycolysis induced by PRL-3. Subsequently, increased glycolysis regulates the IFN-I-stimulated genes by augmenting the activation of STAT1/2.
Insights
Phosphatase of regenerating liver (PRL)-3 drives multiple myeloma cell growth by increasing glycolysis via STAT1/STAT2 activation. This novel circuit links metabolic reprogramming to type 1 interferon signaling in cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Multiple myeloma (MM) is an incurable plasma cell malignancy.
- MM cell survival depends on bone marrow microenvironment interactions.
- Phosphatase of regenerating liver (PRL)-3 is an oncogenic phosphatase overexpressed in MM, mediating metabolic reprogramming.
Purpose of the Study:
- To identify novel pathways and genes regulated by PRL-3 in MM.
- To characterize the global transcriptional response to PRL-3 overexpression.
- To elucidate the functional role of PRL-3 in MM cell metabolism and signaling.
Main Methods:
- Global transcriptional profiling of MM cell lines with PRL-3 overexpression.
- Pathway enrichment analysis to identify regulated pathways.
- In vitro validation experiments, including gene knockdown and metabolic assays.
Main Results:
- PRL-3 overexpression induced genes in the type 1 interferon (IFN-I) signaling pathway via STAT1 and STAT2 activation, independent of autocrine IFN-I secretion.
- STAT1/STAT2 activation and IFN-I stimulated gene expression were decreased by STAT1/2 knockdown, which also reduced PRL-3-induced glycolysis.
- Glucose metabolism was found to contribute to STAT1/STAT2 activation and IFN-I stimulated gene expression in PRL-3 overexpressing cells.
Conclusions:
- PRL-3 activates a novel signaling circuit involving STAT1 and STAT2, driving increased glycolysis in MM cells.
- This circuit links metabolic reprogramming (glycolysis) to the regulation of IFN-I stimulated genes through STAT1/STAT2.
- PRL-3's role in metabolic reprogramming and its interplay with IFN-I signaling pathways represent potential therapeutic targets in multiple myeloma.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
The JAK-STAT Signaling Pathway
cAMP-dependent Protein Kinase Pathways
IP3/DAG Signaling Pathway
Amplifying Signals via Enzymatic Cascade
GPCRs Regulate Adenylyl Cylase Activity

